ABVC Biopharma Inc
ABVC3.200USD
+0.450+16.36%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
49.21MCap. mercado
PérdidaP/E TTM
Más Datos de ABVC Biopharma Inc Compañía
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
Información de la empresa
Símbolo de cotizaciónABVC
Nombre de la empresaABVC Biopharma Inc
Fecha de salida a bolsaNov 09, 2004
Director ejecutivoDr. Uttam Yashwant Patil
Número de empleados16
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 09
Dirección44370 Old Warm Springs Blvd
CiudadFREMONT
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94538-6148
Teléfono15106680881
Sitio Webhttps://abvcpharma.com/
Símbolo de cotizaciónABVC
Fecha de salida a bolsaNov 09, 2004
Director ejecutivoDr. Uttam Yashwant Patil
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Ms. Yen-Hsin Chou
Ms. Yen-Hsin Chou
Independent Director
Independent Director
41.96K
--
Ms. Norimi Sakamoto
Ms. Norimi Sakamoto
Independent Director
Independent Director
41.85K
--
Ms. Hsin-Hui Miao
Ms. Hsin-Hui Miao
Independent Director
Independent Director
41.51K
-13.66%
Mr. Yu- Min (Francis) Chung
Mr. Yu- Min (Francis) Chung
Independent Director
Independent Director
41.39K
-1.33%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
Accionistas
Accionistas
Proporción
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
11.52%
Corporation
4.95%
Investment Advisor
1.02%
Investment Advisor/Hedge Fund
0.81%
Venture Capital
0.36%
Hedge Fund
0.08%
Other
81.25%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
34
3.14M
18.75%
-459.62K
2025Q1
36
3.18M
25.48%
-443.49K
2024Q4
37
3.35M
25.84%
-140.63K
2024Q3
38
3.28M
25.33%
-177.84K
2024Q2
39
3.21M
27.30%
-361.06K
2024Q1
37
3.25M
30.84%
+1.04M
2023Q4
37
1.92M
24.18%
+3.24K
2023Q3
39
1.80M
52.80%
+194.05K
2023Q2
37
1.48M
44.76%
-133.59K
2023Q1
36
1.48M
44.98%
+2.69K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Jiang (Shuling)
1.00M
5.98%
+36.89K
+3.82%
Apr 28, 2025
YuanGene, Corp
829.70K
4.95%
--
--
May 27, 2025
Jiang (Tsung-Shann)
375.99K
2.24%
-47.17K
-11.15%
Apr 28, 2025
Jiang (Eugene)
131.16K
0.78%
--
--
May 27, 2025
Geode Capital Management, L.L.C.
104.48K
0.62%
+25.20K
+31.78%
Mar 31, 2025
The Lind Partners, LLC
94.99K
0.57%
-105.06K
-52.52%
Dec 31, 2024
Patil (Uttam)
72.43K
0.43%
--
--
Apr 28, 2025
XTX Markets LLC
60.44K
0.36%
+26.03K
+75.67%
Mar 31, 2025
Odaira (Yoshinobu)
57.76K
0.34%
--
--
Apr 28, 2025
The Vanguard Group, Inc.
46.95K
0.28%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Fecha
Tipo
Relación
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
